Protocol Ledger

NCT05063734 · Phase II · TERMINATED

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

Interventional Phase II clinical trial protocol NCT05063734 sponsored by Oxurion in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-27 Enrollment: 16 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05063734
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)16 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05063734
Protocol FieldVerified Registry Value
NCT IdentifierNCT05063734
Consolidated Lead SponsorOxurion
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment16 participants (ACTUAL)
Registered Start Date2021-08-27
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05063734
Hospital Research SiteLocationSite Profile
Sierra Eye AssociatesReno, NVOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI